Novo Nordisk: promising results for semaglitude
(CercleFinance.com) - Novo Nordisk has announced top-line results from OASIS 1, a Phase 3 trial in the global OASIS program.
This 68-week efficacy and safety trial compares semaglutide 50 mg orally once daily for weight management to placebo in 667 overweight and obese adults with one or more comorbidities.
Those treated with 50mg of oral semaglutide achieved a statistically significant weight loss of 17.4% after 68 weeks, compared to a 1.8% reduction with placebo. In the trial, oral semaglutide 50 mg was found to be safe and well tolerated.
Novo Nordisk says that the choice between a daily tablet and a weekly injection in the treatment of obesity may offer patients and healthcare providers the opportunity to choose what is best for individual treatment preferences.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This 68-week efficacy and safety trial compares semaglutide 50 mg orally once daily for weight management to placebo in 667 overweight and obese adults with one or more comorbidities.
Those treated with 50mg of oral semaglutide achieved a statistically significant weight loss of 17.4% after 68 weeks, compared to a 1.8% reduction with placebo. In the trial, oral semaglutide 50 mg was found to be safe and well tolerated.
Novo Nordisk says that the choice between a daily tablet and a weekly injection in the treatment of obesity may offer patients and healthcare providers the opportunity to choose what is best for individual treatment preferences.
Copyright (c) 2023 CercleFinance.com. All rights reserved.